Skip to main content
Erschienen in: ästhetische dermatologie & kosmetologie 6/2018

05.12.2018 | Ästhetische Dermatologie | Zertifizierte Fortbildung

Von der Alopecia areata bis zum metabolischen Syndrom

Psoriasis und Komorbidität

verfasst von: PD Dr. med. Arnd Jacobi, M.A.

Erschienen in: ästhetische dermatologie & kosmetologie | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei Patienten mit Psoriasis schränken häufig komorbide Störungen die Lebensqualität zusätzlich ein. Dazu tragen auch Stigmatisierung und Unverständnis gegenüber den Betroffenen bei. Ursache dafür sind vor allem die Äußerlich sichtbaren Erkrankungssymptome. Hier kann die Ästhetische Dermatologie entscheidend Einfluss nehmen, wenn sie in das Gesamtbehandlungskonzept der Psoriasis implementiert wird.
Literatur
2.
Zurück zum Zitat Augustin M et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol. 2012; 26 Suppl 4:1–16 PubMedCrossRef Augustin M et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol. 2012; 26 Suppl 4:1–16 PubMedCrossRef
3.
Zurück zum Zitat Schäfer I et al. Epidemiologie der Psoriasis in Deutschland — Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung. Gesundheitswesen. 2011;73: 308–13 PubMedCrossRef Schäfer I et al. Epidemiologie der Psoriasis in Deutschland — Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung. Gesundheitswesen. 2011;73: 308–13 PubMedCrossRef
4.
Zurück zum Zitat Schmid-Ott G et al. Psychosoziale Folgen der Psoriasis — eine empirische Studie über die Krankheitslast bei 3753 Betroffenen. Hautarzt. 2005; 56: 466–72 PubMedCrossRef Schmid-Ott G et al. Psychosoziale Folgen der Psoriasis — eine empirische Studie über die Krankheitslast bei 3753 Betroffenen. Hautarzt. 2005; 56: 466–72 PubMedCrossRef
5.
Zurück zum Zitat Alpsoy E et al. Internalized stigma in psoriasis: a multicenter study. J Dermatol. 2017; 44: 885–91 PubMedCrossRef Alpsoy E et al. Internalized stigma in psoriasis: a multicenter study. J Dermatol. 2017; 44: 885–91 PubMedCrossRef
6.
Zurück zum Zitat Hawro M et al. Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. J Am Acad Dermatol. 2017; 76: 648–54 PubMedCrossRef Hawro M et al. Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. J Am Acad Dermatol. 2017; 76: 648–54 PubMedCrossRef
7.
Zurück zum Zitat Masaki S et al. Treatment satisfaction, willingness to pay and quality of life in Japanese patients with psoriasis. J Dermatol. 2017; 44:143–6 PubMedCrossRef Masaki S et al. Treatment satisfaction, willingness to pay and quality of life in Japanese patients with psoriasis. J Dermatol. 2017; 44:143–6 PubMedCrossRef
8.
Zurück zum Zitat Schöffski O et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: Amulit-centre study. JDDG. 2007; 3: 209–18 CrossRef Schöffski O et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: Amulit-centre study. JDDG. 2007; 3: 209–18 CrossRef
9.
Zurück zum Zitat Asahina A et al. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: long-term differential effects of biologics. J Dermatol. 2016; 43:779–84 PubMedCrossRef Asahina A et al. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: long-term differential effects of biologics. J Dermatol. 2016; 43:779–84 PubMedCrossRef
10.
Zurück zum Zitat Takata T et al. Detection of asymptomatic enthesitis in psoriasis patients: an onset of psoriatic arthritis? J Dermatol. 2016; 43: 650–4 PubMedCrossRef Takata T et al. Detection of asymptomatic enthesitis in psoriasis patients: an onset of psoriatic arthritis? J Dermatol. 2016; 43: 650–4 PubMedCrossRef
11.
Zurück zum Zitat Yamamoto T et al. Epidemiological analysis of psoriatic arthritis patients in Japan. J Dermatol. 2016; 43:1193–6 PubMedCrossRef Yamamoto T et al. Epidemiological analysis of psoriatic arthritis patients in Japan. J Dermatol. 2016; 43:1193–6 PubMedCrossRef
12.
Zurück zum Zitat Yamamoto T et al. Prevalence and current therapies of psoriatic arthritis in Japan: a survey by the Japanese Society of Psoriasis Research in 2016. J Dermatol. 2017; 44: e121 PubMedCrossRef Yamamoto T et al. Prevalence and current therapies of psoriatic arthritis in Japan: a survey by the Japanese Society of Psoriasis Research in 2016. J Dermatol. 2017; 44: e121 PubMedCrossRef
13.
Zurück zum Zitat Stuart PE et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. 2015; 97: 816–36 PubMedPubMedCentralCrossRef Stuart PE et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. 2015; 97: 816–36 PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Reich K et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. BJD. 2009; 160: 1040–7 CrossRef Reich K et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. BJD. 2009; 160: 1040–7 CrossRef
15.
Zurück zum Zitat Zachariae H et al. Quality of Life and Prevalence of Arthritis Reported by 5,795 Members of the Nordic Psoriasis Associations - Data from the Nordic Quality of Life Study. Acta Derm Venereol. 2002; 82: 108–13 PubMedCrossRef Zachariae H et al. Quality of Life and Prevalence of Arthritis Reported by 5,795 Members of the Nordic Psoriasis Associations - Data from the Nordic Quality of Life Study. Acta Derm Venereol. 2002; 82: 108–13 PubMedCrossRef
16.
17.
Zurück zum Zitat Koch M et al. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol. 2015; 135: 1283–93 PubMedPubMedCentralCrossRef Koch M et al. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol. 2015; 135: 1283–93 PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Parisi R et al. Psoriasis and the risk of major cardiovascular events: cohort study using the Clinical Practice Research Datalink. J Invest Dermatol. 2015; 135: 2189–97 PubMedCrossRef Parisi R et al. Psoriasis and the risk of major cardiovascular events: cohort study using the Clinical Practice Research Datalink. J Invest Dermatol. 2015; 135: 2189–97 PubMedCrossRef
19.
Zurück zum Zitat Lonnberg AS et al. Association of psoriasis with the risk for type 2 diabetes mellitus and obesity. JAMA Dermatol. 2016; 152: 761–7 PubMedCrossRef Lonnberg AS et al. Association of psoriasis with the risk for type 2 diabetes mellitus and obesity. JAMA Dermatol. 2016; 152: 761–7 PubMedCrossRef
20.
Zurück zum Zitat Cohen AD et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008; 22: 585–9 PubMedCrossRef Cohen AD et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008; 22: 585–9 PubMedCrossRef
21.
Zurück zum Zitat Naito R, Imafuku S. Distinguishing features of body mass index and psoriasis in men and women in Japan: a hospital-based case-control study. J Dermatol. 2016; 43: 1406–11 PubMedCrossRef Naito R, Imafuku S. Distinguishing features of body mass index and psoriasis in men and women in Japan: a hospital-based case-control study. J Dermatol. 2016; 43: 1406–11 PubMedCrossRef
22.
Zurück zum Zitat Liu JH et al. Relation between endothelial progenitor cells and arterial stiffness in patients with psoriasis. J Dermatol. 2016; 43: 888–93 PubMedCrossRef Liu JH et al. Relation between endothelial progenitor cells and arterial stiffness in patients with psoriasis. J Dermatol. 2016; 43: 888–93 PubMedCrossRef
23.
Zurück zum Zitat Honma M et al. Close correlation of bone mineral density and body mass index in Japanese psoriasis patients. J Dermatol. 2017; 44: e1–2 PubMedCrossRef Honma M et al. Close correlation of bone mineral density and body mass index in Japanese psoriasis patients. J Dermatol. 2017; 44: e1–2 PubMedCrossRef
24.
Zurück zum Zitat Chularojanamontri L et al. Metabolic syndrome and psoriasis severity in South-East Asian patients: an investigation of potential association using current and chronological assessments. J Dermatol. 2016; 43: 1424–8 PubMedCrossRef Chularojanamontri L et al. Metabolic syndrome and psoriasis severity in South-East Asian patients: an investigation of potential association using current and chronological assessments. J Dermatol. 2016; 43: 1424–8 PubMedCrossRef
26.
Zurück zum Zitat Oh EH et al. Epidemiology and cardiovascular comorbidities in patients with psoriasis: a Korean nationwide population-based cohort study. J Dermatol. 2017; 44: 621–9 PubMedCrossRef Oh EH et al. Epidemiology and cardiovascular comorbidities in patients with psoriasis: a Korean nationwide population-based cohort study. J Dermatol. 2017; 44: 621–9 PubMedCrossRef
27.
Zurück zum Zitat Jacobi A et al. Prevalence of Obesity in Patients with Psoriasis: Results of the National Study PsoHealth3. Dermatology. 2015; 231: 231–8 PubMedCrossRef Jacobi A et al. Prevalence of Obesity in Patients with Psoriasis: Results of the National Study PsoHealth3. Dermatology. 2015; 231: 231–8 PubMedCrossRef
28.
Zurück zum Zitat Kim DS et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016; 43: 305–10 PubMedCrossRef Kim DS et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016; 43: 305–10 PubMedCrossRef
29.
Zurück zum Zitat Pina T et al. Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor-a therapy. J Dermatol. 2016; 43: 389–94 PubMedCrossRef Pina T et al. Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor-a therapy. J Dermatol. 2016; 43: 389–94 PubMedCrossRef
30.
Zurück zum Zitat Sato Y et al. S100A7 expression levels in coordination with interleukin-8 indicate the clinical response to infliximab for psoriasis patients. J Dermatol. 2017; 44: 838–9 PubMedCrossRef Sato Y et al. S100A7 expression levels in coordination with interleukin-8 indicate the clinical response to infliximab for psoriasis patients. J Dermatol. 2017; 44: 838–9 PubMedCrossRef
31.
Zurück zum Zitat Takahashi T et al. Serum angiopoietin-2 level as a potential biomarker in psoriasis vulgaris. J Dermatol. 2017; 44: 205–6 PubMedCrossRef Takahashi T et al. Serum angiopoietin-2 level as a potential biomarker in psoriasis vulgaris. J Dermatol. 2017; 44: 205–6 PubMedCrossRef
32.
Zurück zum Zitat Davidovici BB et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and comorbid conditions. J Invest Dermatol. 2010; 130: 1785–96 PubMedCrossRef Davidovici BB et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and comorbid conditions. J Invest Dermatol. 2010; 130: 1785–96 PubMedCrossRef
34.
Zurück zum Zitat Prinz JC. Autoimmune aspects of psoriasis: heritability and autoantigens. Autoimmun Rev. 2017; 16: 970–9 PubMedCrossRef Prinz JC. Autoimmune aspects of psoriasis: heritability and autoantigens. Autoimmun Rev. 2017; 16: 970–9 PubMedCrossRef
35.
Zurück zum Zitat Akiyama M et al. Association of psoriasis with Hashimoto’s thyroiditis, Sjögren’s syndrome and dermatomyositis. J Dermatol. 2016; 43: 711–2 PubMedCrossRef Akiyama M et al. Association of psoriasis with Hashimoto’s thyroiditis, Sjögren’s syndrome and dermatomyositis. J Dermatol. 2016; 43: 711–2 PubMedCrossRef
36.
Zurück zum Zitat Maki N et al. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia. J Dermatol. 2016; 43: 571–4 PubMedCrossRef Maki N et al. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia. J Dermatol. 2016; 43: 571–4 PubMedCrossRef
37.
Zurück zum Zitat Matsuo H et al. Relapsing polychondritis associated with psoriasis vulgaris successfully treated with adalimumab: a case report with published work review. J Dermatol. 2017; 44: 826–9 PubMedCrossRef Matsuo H et al. Relapsing polychondritis associated with psoriasis vulgaris successfully treated with adalimumab: a case report with published work review. J Dermatol. 2017; 44: 826–9 PubMedCrossRef
38.
Zurück zum Zitat Jacobi A, Kupke C, Behzad M, Hertl M. Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study. Int J Dermatol. 2013; 52: 1081–7 PubMedCrossRef Jacobi A, Kupke C, Behzad M, Hertl M. Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study. Int J Dermatol. 2013; 52: 1081–7 PubMedCrossRef
40.
Zurück zum Zitat Gelfand JM et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007; 143: 1493–9 PubMed Gelfand JM et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007; 143: 1493–9 PubMed
41.
Zurück zum Zitat Augustin M et al. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta DermVenereol. 2010; 90: 147–51 Augustin M et al. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta DermVenereol. 2010; 90: 147–51
42.
Zurück zum Zitat Dorschner RA et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol. 2001; 117: 91–7 PubMedCrossRef Dorschner RA et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol. 2001; 117: 91–7 PubMedCrossRef
44.
Zurück zum Zitat Lande R et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007; 449: 564–9 PubMedCrossRef Lande R et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007; 449: 564–9 PubMedCrossRef
46.
Zurück zum Zitat Teng MW et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015; 21: 719–29 PubMedCrossRef Teng MW et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015; 21: 719–29 PubMedCrossRef
47.
Zurück zum Zitat Boniface K et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005; 174: 3695–702 PubMedCrossRef Boniface K et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005; 174: 3695–702 PubMedCrossRef
48.
Zurück zum Zitat Sa SM et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007; 178: 2229–40 PubMedCrossRef Sa SM et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007; 178: 2229–40 PubMedCrossRef
49.
Zurück zum Zitat Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidencebased conclusions. J Am Acad Dermatol. 2011; 65: 137–74 PubMedCrossRef Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidencebased conclusions. J Am Acad Dermatol. 2011; 65: 137–74 PubMedCrossRef
50.
Zurück zum Zitat Jabbar-Lopez ZK et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017; 137: 1646–54 PubMedPubMedCentralCrossRef Jabbar-Lopez ZK et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017; 137: 1646–54 PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Torii H et al. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: results of the SPREAD study. J Dermatol. 2017; 44: 552–9 PubMedCrossRef Torii H et al. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: results of the SPREAD study. J Dermatol. 2017; 44: 552–9 PubMedCrossRef
52.
Zurück zum Zitat Torii H et al. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: results from the prospective post-marketing surveillance. J Dermatol. 2016; 43: 767–78 PubMedCrossRef Torii H et al. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: results from the prospective post-marketing surveillance. J Dermatol. 2016; 43: 767–78 PubMedCrossRef
53.
Zurück zum Zitat Imafuku S et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016; 43: 1011–7 PubMedCrossRef Imafuku S et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016; 43: 1011–7 PubMedCrossRef
54.
Zurück zum Zitat Asahina A et al. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: results of SALSA study. J Dermatol. 2016; 43: 1257–66 PubMedPubMedCentralCrossRef Asahina A et al. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: results of SALSA study. J Dermatol. 2016; 43: 1257–66 PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Saeki H et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017; 44: 355–62 PubMedCrossRef Saeki H et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017; 44: 355–62 PubMedCrossRef
56.
Zurück zum Zitat Matsumoto A et al. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis. J Dermatol. 2017; 44: 202–4 PubMedCrossRef Matsumoto A et al. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis. J Dermatol. 2017; 44: 202–4 PubMedCrossRef
57.
Zurück zum Zitat Hwang YJ et al. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis. J Dermatol. 2017; 44: 560–6 PubMedCrossRef Hwang YJ et al. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis. J Dermatol. 2017; 44: 560–6 PubMedCrossRef
58.
Zurück zum Zitat Lande R et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014; 5: 5621 PubMedCrossRef Lande R et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014; 5: 5621 PubMedCrossRef
59.
Zurück zum Zitat Lande R et al. Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. Eur J Immunol. 2015; 45: 203–13 PubMedCrossRef Lande R et al. Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. Eur J Immunol. 2015; 45: 203–13 PubMedCrossRef
62.
Zurück zum Zitat Gudjonsson JE et al. HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol. 2002; 118: 362–5 PubMedCrossRef Gudjonsson JE et al. HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol. 2002; 118: 362–5 PubMedCrossRef
63.
Zurück zum Zitat Gudjonsson JE et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol. 2003; 148: 233–5 PubMedCrossRef Gudjonsson JE et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol. 2003; 148: 233–5 PubMedCrossRef
64.
Zurück zum Zitat Plewig G et al. Braun-Falco’s Dermatologie, Venerologie und Allergologie. 6. überarbeitete und erweiterte Auflage. Berlin, Heidelberg: Springer; 2012 Plewig G et al. Braun-Falco’s Dermatologie, Venerologie und Allergologie. 6. überarbeitete und erweiterte Auflage. Berlin, Heidelberg: Springer; 2012
65.
Zurück zum Zitat Tsai TF et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011; 63: 40–6 PubMedCrossRef Tsai TF et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011; 63: 40–6 PubMedCrossRef
66.
Zurück zum Zitat Wu JJ et al. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012; 67: 924–30 PubMedCrossRef Wu JJ et al. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012; 67: 924–30 PubMedCrossRef
67.
Zurück zum Zitat Kridin K, Bergman R. Association between bullous pemphigoid and psoriasis: a case-control study. J Am Acad Dermatol. 2017; 77: 370–2 PubMedCrossRef Kridin K, Bergman R. Association between bullous pemphigoid and psoriasis: a case-control study. J Am Acad Dermatol. 2017; 77: 370–2 PubMedCrossRef
68.
Zurück zum Zitat Ohata C et al. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: a series of 145 cases. J Am Acad Dermatol. 2015; 73: 50–5 PubMedCrossRef Ohata C et al. Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: a series of 145 cases. J Am Acad Dermatol. 2015; 73: 50–5 PubMedCrossRef
69.
Zurück zum Zitat Chen YJ et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011; 165: 593–9 PubMedCrossRef Chen YJ et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011; 165: 593–9 PubMedCrossRef
70.
Zurück zum Zitat Arunachalam M et al. Non-seg- mental vitiligo and psoriasis comorbidity — a case-control study in Italian patients. J Eur Acad Dermatol Venereol. 2014; 28: 433–7 PubMedCrossRef Arunachalam M et al. Non-seg- mental vitiligo and psoriasis comorbidity — a case-control study in Italian patients. J Eur Acad Dermatol Venereol. 2014; 28: 433–7 PubMedCrossRef
71.
Zurück zum Zitat Blegvad C et al. Autoimmune disease in children and adolescents with psoriasis: a cross-sectional study in Denmark. Acta Derm Venereol. 2017; 97: 1225–29 PubMedCrossRef Blegvad C et al. Autoimmune disease in children and adolescents with psoriasis: a cross-sectional study in Denmark. Acta Derm Venereol. 2017; 97: 1225–29 PubMedCrossRef
73.
Zurück zum Zitat Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995; 32: 982–6 PubMedCrossRef Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995; 32: 982–6 PubMedCrossRef
74.
Zurück zum Zitat Ludwig RJ et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007; 156: 271–6 PubMedCrossRef Ludwig RJ et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007; 156: 271–6 PubMedCrossRef
75.
Zurück zum Zitat Patel RV et al. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011; 26: 1036–49 PubMedPubMedCentralCrossRef Patel RV et al. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011; 26: 1036–49 PubMedPubMedCentralCrossRef
76.
Zurück zum Zitat Mallbris L et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004; 19: 225–30 PubMedCrossRef Mallbris L et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004; 19: 225–30 PubMedCrossRef
77.
Zurück zum Zitat Gelfand JM et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296: 1735–41 PubMedCrossRef Gelfand JM et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296: 1735–41 PubMedCrossRef
78.
Zurück zum Zitat Boehncke WH et al. The ‚psoriatic march‘: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011; 20: 303–7 PubMedCrossRef Boehncke WH et al. The ‚psoriatic march‘: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011; 20: 303–7 PubMedCrossRef
79.
Zurück zum Zitat Jacobsson LT et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascuar events in patients with rheumatoid arthritis. J Rheumatol. 2005. 32: 1213–8 PubMed Jacobsson LT et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascuar events in patients with rheumatoid arthritis. J Rheumatol. 2005. 32: 1213–8 PubMed
80.
Zurück zum Zitat Wolk K et al. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol. 2009; 89: 492–7 PubMedCrossRef Wolk K et al. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol. 2009; 89: 492–7 PubMedCrossRef
81.
Zurück zum Zitat Setty AR et al. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med. 2007; 167: 1670–5 PubMedCrossRef Setty AR et al. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med. 2007; 167: 1670–5 PubMedCrossRef
82.
Zurück zum Zitat Van Kruijsdijk RC et al. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2569–78 PubMedCrossRef Van Kruijsdijk RC et al. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2569–78 PubMedCrossRef
84.
Zurück zum Zitat weltpsoriasistag.de [Internet]. Hamburg: Competenzzentrum Versorgungsforschung in der Dermatologie Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen [zitiert am 22.10.2018]. Verfügbar unter www.​weltpsoriasistag​.​de weltpsoriasistag.de [Internet]. Hamburg: Competenzzentrum Versorgungsforschung in der Dermatologie Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen [zitiert am 22.10.2018]. Verfügbar unter www.​weltpsoriasistag​.​de
85.
Zurück zum Zitat Kerscher M. Dermatokosmetik. 2. bearbeitete und erweiterte Auflage. Berlin Hedielberg: Springer; 2009 Kerscher M. Dermatokosmetik. 2. bearbeitete und erweiterte Auflage. Berlin Hedielberg: Springer; 2009
Metadaten
Titel
Von der Alopecia areata bis zum metabolischen Syndrom
Psoriasis und Komorbidität
verfasst von
PD Dr. med. Arnd Jacobi, M.A.
Publikationsdatum
05.12.2018
Verlag
Springer Medizin
Erschienen in
ästhetische dermatologie & kosmetologie / Ausgabe 6/2018
Print ISSN: 1867-481X
Elektronische ISSN: 2198-6517
DOI
https://doi.org/10.1007/s12634-018-5563-y

Weitere Artikel der Ausgabe 6/2018

ästhetische dermatologie & kosmetologie 6/2018 Zur Ausgabe

Passend zum Thema

Spektrum Dermatologie 2.0 – Der digitale Fortbildungskongress
ANZEIGE

Spektrum Dermatologie 2.0 – Der digitale Fortbildungskongress

Der Fortbildungskongress Spektrum Dermatologie 2.0 „Ästhetische und klinische Dermatologie: Präzise Interventionen und optionale Nachbehandlung“ am 27. Oktober 2023 knüpft am großen Erfolg letzten Jahres an. 9 Expert*innen referieren zu aktuellen Herausforderungen in der ästhetischen und klinischen Dermatologie und geben somit einen guten Gesamtüberblick.

Bevorstehende Anhebungswelle der UV GOÄ zum 1.7.2023
ANZEIGE

Bevorstehende Anhebungswelle der UV GOÄ zum 1.7.2023

Wo gibt es denn sowas? Eine lineare Anhebung einer kompletten Gebührenordnung um 5%? (Leider) nur bei der gesetzlichen Unfallversicherung (UV GOÄ [Gebührenordnung für Ärzte]) – und das nicht nur in diesem Jahr, sondern über insgesamt fünf Jahre bis 2027. Es wird Zeit, dass andere nachziehen und in Praxen und Kliniken Planungssicherheit schaffen.

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut
ANZEIGE

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.

Passend zum Thema

ANZEIGE
Cal/Bet-Sprühschaum überzeugt Ärzte und Patienten
Hohe Zufriedenheit

Cal/Bet-Sprühschaum überzeugt Ärzte und Patienten

Durch Läsionen an Kopfhaut und Körper leiden Psoriasis-Betroffene häufig an Stigmatisierung. Wirksame Therapien, die die Symptome schnell verbessern, sind somit auch für die psychosoziale Gesundheit von hoher Relevanz [2]. Der Cal/Bet-Sprühschaumi bietet hier eine effektive Lösung.

Passend zum Thema

Deucravacitinib – neuer First-in-Class-Wirkstoff bei Plaque-Psoriasis

Deucravacitinib – neuer First-in-Class-Wirkstoff bei Plaque-Psoriasis

Deucravacitinib von Bristol Myers Squibb ist ein selektiver, allosterischer Tyrosinkinase-2-Inhibitor und der erste Vertreter dieser neuen Klasse niedermolekularer Wirkstoffe. Eingesetzt wird das oral einzunehmende Medikament zur systemischen Behandlung Erwachsener mit mittelschwerer bis schwerer Plaque-Psoriasis.